Physician profile
Joseph Kipp
NPI 1154331452
$12,599.71
in general payments reported to CMS, 2019-2025
59 companies · $2,303 in 2025
The $2,303 reported for 2025 was more than what 97% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $461 · 2020: $557 · 2021: $1,468 · 2022: $2,112 · 2023: $2,806 · 2024: $2,893 · 2025: $2,303.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,002.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,002.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,547.71 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,202.39 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $1,131.02 | 2019-2025 | Wegovy |
| Glaxosmithkline, LLC. | $816.35 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Lilly USA, LLC | $698.36 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Astellas Pharma US INC | $584.62 | 2019-2025 | Veozah |
| Sumitomo Pharma America, INC. | $548.47 | 2023-2025 | Gemtesa |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $530.73 | 2022-2025 | Xifaxan |
| Pfizer INC. | $477.66 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $422.63 | 2019-2025 | Verquvo, Belsomra, Steglatro |
| Otsuka America Pharmaceutical, INC. | $413.16 | 2020-2025 | Rexulti |
| Esperion Therapeutics, INC. | $338.59 | 2021-2025 | Nexletol |
| Boehringer Ingelheim Pharmaceuticals, INC. | $325.42 | 2020-2025 | Jardiance, Spiriva Respimat, Stiolto Respimat |
| Gilead Sciences, INC. | $279.82 | 2022-2025 | |
| Exact Sciences Corporation | $272.10 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
Show all 59 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Kipp listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.